Meta-analysis of the Efficacy of Sorafenib for Hepatocellular Carcinoma |
Wang, Zhao
(Department of Digestion,Chengdu Military General Hospital)
Wu, Xiao-Ling (Department of Digestion,Chengdu Military General Hospital) Zeng, Wei-Zheng (Department of Digestion,Chengdu Military General Hospital) Xu, Gui-Sen (Department of Emergency, Chengdu Military General Hospital) Xu, Hui (Department of Digestion,Chengdu Military General Hospital) Weng, Min (Department of Digestion,Chengdu Military General Hospital) Hou, Juan-Ni (Department of Digestion,Chengdu Military General Hospital) Jiang, Ming-De (Department of Digestion,Chengdu Military General Hospital) |
1 | Abou-Alfa GK, Johnson P, Knox JJ, et al (2010). Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma. JAMA, 304, 2154-60. DOI ScienceOn |
2 | Chen KF, Chen HL, Tai WT, et al (2011). Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells. J Pharmcol Exp Ther, 337, 155-61. DOI ScienceOn |
3 | Cheng AL, Kang YK, Chen Z, et al (2009). Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol, 10, 25-34. DOI ScienceOn |
4 | Dal Lago L, D'Hondt V, Awada A (2008). Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors. Oncologist, 13, 845-58. DOI ScienceOn |
5 | Escudier B, Eisen T, Stadler WM, et al (2007). Sorafenib in advanced clear-cell renal-cell carcinoma. New Engl J Med, 356, 125-34. DOI ScienceOn |
6 | Escudier B, Eisen T, Stadler WM, et al (2009). Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol, 27, 3312-8. DOI ScienceOn |
7 | Furuse J, Ishii H, Nakachi K, et al (2008). Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci, 99, 159-65. |
8 | Huitzil-Melendez F, Saltz L, Song J, et al (2008). Retrospective analysis of outcome in hepatocellular carcinoma (HCC) patients (pts) with hepatitis C (C+) versus B (B+) treated with sorafenib (S). In: 2007 Gastrointestinal Cancers Symposium. |
9 | Jemal A, Murray T, Ward E, et al (2005). Cancer statistics, 2005. CA Cancer J Clin, 55, 10-30. DOI ScienceOn |
10 | Kudo M, Imanaka K, Chida N, et al (2011). Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer, 47, 2117-27. DOI ScienceOn |
11 | Liu L, Cao Y, Chen C, et al (2006). Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res, 66, 11851-8. DOI ScienceOn |
12 | Wilhelm S, Carter C, Lynch M, et al (2006). Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov, 5, 835-44. DOI ScienceOn |
13 | Llovet JM, Ricci S, Mazzaferro V, et al (2008). Sorafenib in advanced hepatocellular carcinoma. New Engl J Med, 359, 378-90. DOI ScienceOn |
14 | Parkin DM, Pisani P, Ferlay J (2008). Global cancer statistics. CA Cancer J Clin, 49, 33-64. |
15 | Villanueva A, Newell P, Chiang DY, et al (2007). Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis, 27, 55-76. DOI ScienceOn |